Schondelmeyer S W
Drug Inf J. 1985;19(2):185-93. doi: 10.1177/009286158501900221.
The future holds great promise for the Rx-to-OTC switch, if we will collectively plan and manage that process. The impact of Rx-to-OTC switches will extend far beyond the technical and regulatory issues and implications. Certainly, pharmaceutical manufacturers, the Food and Drug Administration, and the Federal Trade Commission are at the center of this issue, but no less important are the roles of physicians, pharmacists, and consumers. The social and economical, and even logistical, aspects of the switch process should be considered as antecedents to an Rx-to-OTC switch policy, rather than as consequences to be measured after such a policy has been determined. Finally, the evolution of an Rx-to-OTC switch policy in the coming months and years should avoid the path of political and administrative expediency and it should avoid the consideration of special interests in isolation from the broader social context. The development of a sound Rx-to-OTC switch policy will occur only if the direction and demand truly comes from within the ranks of the consumers.
如果我们能共同规划和管理处方药转非处方药的转换过程,那么未来前景广阔。处方药转非处方药转换的影响将远远超出技术和监管问题及影响。当然,制药商、食品药品监督管理局和联邦贸易委员会是这个问题的核心,但医生、药剂师和消费者的作用同样重要。转换过程的社会、经济乃至物流方面应被视为处方药转非处方药转换政策的前提,而非在确定此类政策后才衡量的结果。最后,未来几个月和几年处方药转非处方药转换政策的演变应避免政治和行政权宜之计的道路,应避免脱离更广泛的社会背景孤立地考虑特殊利益。只有当方向和需求真正来自消费者群体内部时,健全的处方药转非处方药转换政策才会得以制定。